tifcemalimab

Tifcemalimab is a recombinant humanized immunoglobulin G4 kappa (IgG4κ) monoclonal antibody that targets the B- and T-lymphocyte attenuator (BTLA), an inhibitory co-signaling receptor expressed on B cells, T cells, and NK cells[1][5][6]. By binding to BTLA, tifcemalimab blocks its interaction with its ligand HVEM (Herpes virus entry mediator), thereby inhibiting the BTLA-mediated immunosuppressive signaling pathway. This blockade activates tumor-specific lymphocytes by preventing the inhibition of immune responses that normally occurs through BTLA-HVEM signaling[3][8]. Tifcemalimab is being developed primarily for cancer immunotherapy and has shown preliminary antitumor activity as monotherapy or in combination with toripalimab (an anti-PD-1 antibody) in advanced malignancies such as small cell lung cancer and esophageal squamous cell carcinoma[2][5][8]. The drug was independently developed by Junshi Biosciences.

Other names

icatolimabImmunoglobulin g4, anti-(human b and t lymphocyte attenuator (btla)) (human-mus musculus monoclonal js004 .gamma.4-chain), disulfide with human-mus musculus monoclonal js004 .kappa.-chain, dimer